Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer ...

The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from ...

Pfizer Inc. is offering around 700 million shares in Haleon Plc, representing a roughly 7.7% stake in the maker of Sensodyne ...

Pfizer is looking to sell about 700 million ordinary shares in Haleon, its bookrunner J.P. Morgan said on Tuesday, lowering ...

Pfizer divests $3.05 billion of Haleon shares, cutting its stake to 7.3% in a strategic shift to refocus on core ...

Wednesday announced the sale of 700 million shares in Haleon Plc (HLN), a British multinational consumer healthcare ...

Pfizer has further reduced its holding in Haleon, it was confirmed on Wednesday, after the drugs giant offloaded 700m shares ...

Pfizer plans to cut its stake in Haleon through an accelerated bookbuilding process to institutional investor, starting immediately.

In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 could turn out.

The latest disposal reduced Pfizer's interest in Haleon to 7.3% from 15%. JPMorgan and Morgan Stanley acted as joint global coordinators and joint bookrunners for the sale. GSK sold its remaining 4.2% ...

Pfizer Inc the American multinational pharmaceutical and biotechnology corporation is offering around 700 million shares in Haleon Plc representin ...

On the corporate front, Currys has raising profits guidance alongside a strong festive update. Pubs chain Mitchells & Butlers ...